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Previous reports have highlighted the suboptimal utilization and prescription of statin ther-
apy among patients with type 2 diabetes mellitus (T2DM) in the Malaysian clinical practice.
This study aims to test the impact of a pharmacist-led academic detailing program on
improving the overall statin therapy prescribing in Malaysian hospital and primary care
settings.
Methods
As a quasi-experimental design with a control group and pre-tests., we examined 1,598
medical records of T2DM subjects in six healthcare facilities in the state of Pahang, Malay-
sia. In all study sites, there was a pre and post-intervention assessment of the percentage of
appropriate statin therapy prescribing that complied with the clinical guidelines with no
potential safety issues. The intervention was an academic detailing program offered to the
health care providers in three study sites, while the other three sites served as the control
group. A comparison of the overall percentage of appropriate statin therapy prescribing
before and after the academic detailing was performed in all intervention and control sites.
Results
Overall, 797 medical records were examined in the pre-intervention phase, and 801 records
were evaluated in the post-intervention phase. The academic detailing program was associ-
ated with a statistically significant difference in the proportion of appropriate statin therapy
prescribing between the post-intervention phase compared to the pre-intervention phase (n
= 246, 61.7% versus n = 188, 47.1%), p = 0.001. Whereas, the appropriate statin therapy
prescribing in the control study sites experienced a modest change from 53.8% (214/398) to
56.7% (228/402), p = 0.220. The academic detailing showed significant increases in the pro-
portions of appropriate statin therapy prescribing in both hospital and primary care settings.







Citation: Elnaem MH, Nik Mohamed MH, Huri HZ
(2019) Pharmacist-led academic detailing
improves statin therapy prescribing for Malaysian
patients with type 2 diabetes: Quasi-experimental
design. PLoS ONE 14(9): e0220458. https://doi.
org/10.1371/journal.pone.0220458
Editor: Carl Richard Schneider, The University of
Sydney School of Pharmacy, AUSTRALIA
Received: February 12, 2019
Accepted: July 16, 2019
Published: September 19, 2019
Copyright: © 2019 Elnaem et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and Supporting Information
files.
Funding: This work is supported by Grant Number:
RIGS17-122-0697 from Research Management
Center, International Islamic University Malaysia.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: T2DM, type 2 diabetes mellitus;
LLT, lipid-lowering therapy; CVD, cardiovascular
Conclusions
The academic detailing program was found to be significantly associated with a positive
impact on the overall statin therapy prescribing among patients with T2DM in Malaysian
hospital and primary care settings.
Introduction
The appropriate use of lipid-lowering therapy (LLT), e.g. statin therapy has received increasing
recognition and attention given the treatment gap and undertreatment (18.3% & 35%) of eligi-
ble patients with type 2 diabetes mellitus (T2DM) contradictory to the clinical guidelines rec-
ommendations in the United Kingdom and Malaysia, respectively [1,2]. Furthermore, it has
been reported in a study conducted in the United States that even after reading the clinical
guidelines, healthcare providers could still have gaps in their knowledge regarding the ratio-
nale and importance of the guidelines recommendations [3]. Moreover, a nationwide Indian
study has highlighted that there are inconsistencies between different healthcare providers in
their prescribing practice of LLT that needs to be addressed through additional educational
initiatives and continuous medical education programs [4]. Consequently, promoting compli-
ance with guideline recommendations could help in avoiding potentially preventable chronic
CVD through assuring the effective, safe, and rational use of LLT [5].
In a study by Kuiper et al., to investigate the use of LLT among the high CVD risk popula-
tion in the Netherlands [6], it has been concluded that there are opportunities for quality
improvement interventions to improve the practice related to recommended therapeutic
approaches of CVD prevention. Furthermore, previous research highlighted that pharmacists
could play an important role in optimizing the use of LLT among high CVD risk subjects
through reviewing the current treatment strategies and promoting the usage of high-intensity
statin treatment and ezetimibe-statin combination therapy to enhance the attainment of LDL-
c target values [7,8]. In a previous US study that aimed at evaluating the potential impact of
pharmacists’ intervention on statin therapy, it has been found that overall 35% of pharmacists’
recommendations were accepted and help to optimize statin therapy prescribing [9]. More-
over, it was revealed that the pharmacist-managed program was linked to higher proportions
of subjects achieving their T2DM treatment goals at three and six-month intervals in compari-
son with usual medical care [10].
There is well-established evidence to support achieving possible improvement in the pre-
scribing quality through initiatives tailored for healthcare providers [11]. Also, significant dif-
ferences in many prescribing elements could be achieved through educational intervention,
particularly high-intensity interactive interventions [12]. In particular, academic detailing
could help towards improving the prescribing quality and maintaining a needed balance
between the commercial interests related to the industry and a thorough evidence-based medi-
cine understanding related to academia [13]. Academic detailing can be described in the clini-
cal practice as a multifaceted intervention that typically consists of a visit conducted by the
qualified university-based practitioner to healthcare providers at their practice sites. The aim is
to optimize the prescribing patterns in real practice through the provision of unbiased, evi-
dence-based recommendations on best practices of drug therapies [14].
Academic detailing, a direct educational outreach intervention to promote compliance to
evidence-based recommendations among healthcare providers, has been recognized as one of
the effective educational interventions that help to advance the excellence of care among
T2DM subjects [15]. Accordingly, there are initiatives at various levels that could help in
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improving the effectiveness and quality of prescribing statin medications in the current clinical
practice [16]. One key initiative is the education of healthcare providers’ through the utiliza-
tion of pharmacists as academic detailers which have been associated with international suc-
cess stories to support rigorous, evidence-based, and cost-effective clinical practice [17]. For
example, a cluster-randomized controlled trial piloted in the UK general practice to evaluate
the impact of the interventions of pharmacists on enhancing the statin therapy prescribing
and the achievement of cholesterol treatment goals among high CVD risk patients has revealed
statistically significant improvements in the overall study outcome measures [18].
In Malaysia, national reports on the use of medicines have reported the underutilization and
suboptimal use of lipid-lowering therapy in local clinical settings [19]. Also, the latest national
survey among medical practitioners has highlighted gaps in both their knowledge and practice of
the management of dyslipidemia [20]. Educational interventions could have a fundamental role
in enlightening and promoting the effective, rational, and safe utilization of LLT among high
CVD risk individuals such as T2DM subjects. Our study was aimed at designing and implement-
ing an academic detailing program in Malaysian hospital and primary care settings and test its
impact on improving the overall use of LLT e.g. statin therapy in the clinical practice.
Materials and methods
Study design
A quasi-experimental design with a control group and pre-tests involving six healthcare prac-
tice sites in the state of Pahang, Malaysia. We conducted the first phase at all sites in the form
of cross-sectional studies in order to provide baseline assessment data. Then we conducted the
educational intervention program at three study sites, and the other three sites were consid-
ered as the control group. Subsequently, we conducted the post-intervention phase at all sites
employing similar methods as per the baseline data collection. The assessment of the appropri-
ate prescribing of lipid-lowering therapy for CVD prophylaxis in Malaysian patients with
T2DM was based on the National CPG for the treatment of T2DM published in 2015. We eval-
uated and compared between the appropriate statin therapy prescribing pre and post educa-
tional intervention in all study sites. We included hospitals and primary care clinics in both
intervention and control groups to provide a comprehensive assessment of the educational
intervention. Fig 1 illustrates the overall schematic study design.
First phase: Baseline data collection
The pre-intervention data collection phase involved all eligible Malaysian patients diagnosed
with T2DM from two hospitals and four primary care clinics. The data collection forms were
designed to capture the patient’s demographics, proposed indication for statin therapy, and all
relevant laboratory values. In addition, an overview of underlying diseases, co-prescribed med-
ications, and description of actually or previously prescribed statin therapy were also collected.
The data were collected from medical records and patients’ follow up files. The study sample
was divided into two comparable matched groups; an interventional group and a control
group. Each group involved one hospital and two primary care clinics. The considerations for
setting comparable groups include type and number of study sites in each group, sample size
from each study site and from overall sites in each group, and location of study sites.
Second phase: Intervention
We employed a convenience sampling method to select the health care providers in one hospi-
tal and two primary care clinics (intervention group) referring to the baseline data in the first
Pharmacist-led academic detailing improves statin therapy prescribing
PLOS ONE | https://doi.org/10.1371/journal.pone.0220458 September 19, 2019 3 / 13
phase. An invitation to all health care providers in each facility (medical and pharmacy profes-
sionals) was undertaken to ascertain if they had been and are involved in providing care to
T2DM patients. Acceptance of the invitation meant their enrolment in the intervention phase.
Furthermore, the participating healthcare providers should have no recent or potential (at
least three months following intervention) overlapping duties in one of the healthcare facilities
in the control group.
The intervention was in the form of an academic detailing program regarding cardiovascu-
lar risk reduction with a key focus on enhancing the rational prescribing of statin therapy
among Malaysian type 2 diabetic patients. The purpose of the introductory intervention com-
ponent of the study was to provide an overview of the data in the first phase to provide clearer
profiling of the current prescribing practice. Moreover, to help identify the potential improve-
ment initiatives that could be considered afterward.
All core principles of academic detailing were considered [21] such as:
a) Conducting surveys to investigate baseline knowledge and the motivation for current and
proposed prescribing patterns. In this study, a questionnaire was developed, consisting of 12
items in order to assess the knowledge and perceptions of the current prescribing practice.
b) Establishing credibility through a respected organizational sponsor and unbiased informa-
tion sources. As an academic detailing program, the study was sponsored by a well-estab-
lished and respected academic organization.
c) Using concise and visually appealing graphical educational materials. In this study, the pre-
sentation design contained and considered recent findings regarding statin therapy use in
T2DM patients. The presentation was further supported by printed materials highlighting
the most recently updated evidence related to the clinical benefits and risks associated with
statin therapy in T2DM patients.
d) Stimulating physician participation in two-way interaction. In the educational session, the
concluding component was dedicated to inciting interaction between the participating
health care providers and the main researcher (the presenter). Many interesting points
were discussed and voiced during this interactive discussion. For example, the physician’s
experience with statin-associated muscle symptoms, the combination lipid-lowering
Fig 1. Schematic diagram of the study design.
https://doi.org/10.1371/journal.pone.0220458.g001
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therapy, and the indications for non-statin therapy. We have published a detailed sche-
matic diagram of the program components and the survey used in this program [22].
Third phase: Post-intervention
A post-intervention data collection phase from all intervention and control study sites was con-
ducted with both subjected to intervention and those acting as control sites. From the literature
review, there was no statistical difference evident between the outcome of an assessment follow-
ing the latest educational outreach session at either 3 or 6 months regarding the potential
change in prescribing behavior [23]. Therefore, the assessment of the impact of academic detail-
ing on the prescribing practice was conducted at least three months following the intervention.
Sample size calculation
The calculation was based on the equation of sample size calculation for proportion provided
in the open source epidemiologic statistics for public health that suggested 369 patients’ rec-
ords per study group [24]. As the study design involved two groups, one as the intervention
group and the other as the control, the total expected sample size for the two groups combined
was 738 in each phase. The sample size was further increased to 800 (two groups of 400 each)
to address any missed or rejected cases and to facilitate the distribution of required cases
between the two hospitals (200/each) and the four primary care clinics (100/each). The same
sample size was anticipated to be employed for both the pre and post-intervention phases. The
collection of data from the hospitals consisted of inpatient data while outpatient data were
obtained from the primary care clinics to allow a comparison to be made between inpatient
and outpatient lipid-lowering therapy-prescribing practice among patients with T2DM.
Ethical approval and consent to participate
The study protocol obtained ethical approval from the Medical Research Ethical Committee
(MREC) of the National Medical Research Registry (NMRR) before starting the data collection
procedures. The protocol approval ID is NMRR-16-713-29691 (IRR). Further administrative
approvals were also obtained in each study site upon request. All ethical rules and regulations
were strictly adhered to during the research. The obtained ethical approval permit for conduct-
ing the educational intervention with all healthcare providers in the study sites mentioned
above. Healthcare providers attendance and participation in our intervention imply their ver-
bal consent to take part in our study. As per the obtained approval, there was no need for the
obtainment of written consent from healthcare providers who voluntarily accepted our invita-
tion to participate in our work.
Inclusion criteria
The inclusion criteria incorporated data from the records of T2DM patients over the age of 40
years with or without overt CVD. Notably, all T2DM patients aged 40 to 75 years of age should
receive statin therapy with the aim of CVD prevention regardless of baseline LDL cholesterol
levels [25]. Furthermore, at the time of this study, participants were considered to be eligible if
they were an outpatient referred to one of the four primary care clinics specified earlier; and
an inpatient admitted to hospital (one of the two hospitals specified earlier) in a general medi-
cal ward for not less than 48 hours.
Exclusion criteria
We excluded the records of T2DM patients based on the following criteria:
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➢ Elderly diabetic patients > 75 years.
➢ Hospitalized patients who spent less than 48 hours in the hospital or those admitted to criti-
cal care units because those patients might be experiencing many other active medical and
metabolic abnormalities requiring deterring or temporary discontinuation of statin therapy.
➢ Patients that had any contraindication to receiving statin therapy such as:
• Known active liver diseases.
• End-stage renal failure on dialysis with no prior history of receiving statin therapy.
• History of statin intolerance, which did not improve with prior attempts to change statin
therapy, dosage, and frequency of administration.
Outcome measures
The primary outcome of this study aimed to identify and compare the proportion of patients
on appropriate statin therapy prescribing between intervention and control groups with par-
ticular interest to examine the impact of study educational intervention. The evaluation of the
appropriateness of statin therapy prescribing was mainly based on the 2015 Malaysian CPG
for the treatment of patients with T2DM; recommending statin therapy for all patients
between 40 and 75 years of age. The output of the evaluation process was classified into three
main classifications, which were considered appropriate, inappropriate, or potentially inap-
propriate. The working definitions of these three classifications of statin therapy assessment
are depicted in Table 1.
Statistical analysis
All completed data collection sheets were included in the data analysis. Descriptive statistics
using frequencies and proportions were used to describe the prevalence and evaluation of
statin therapy prescribing among Malaysian patients with T2DM. Also, the Chi-square test of
homogeneity was performed to compare the prevalence of statin therapy prescribing across
the different study sites before and after the intervention, and the level of significance was set
at P< 0.05. Data were analyzed using the Statistical Package for the Social Sciences (SPSS v.22
software. (IBM SPSS Statistics, NC, USA).
Results
Patients’ distribution in study sites and the demographic characteristics
In total, 782 records were examined in the hospital setting; 393 for the pre-intervention and
389 for the post-intervention phase. A total of 816 records were reviewed in the primary care




Appropriate Recommended intensity statin regimen (moderate or high intensity) for patients with
high CVD risk and no potential statin-drug interaction
Inappropriate No Statin Therapy Prescriptions




Low-intensity statin in high CVD risk patients
Renal dose adjustment is required for the prescribed statin regimen
https://doi.org/10.1371/journal.pone.0220458.t001
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setting; 404 for the pre-intervention phase and 412 for the post-intervention phase. The mean
age of the study participants was 60.26 ± 8.55 and 59.05 ± 8.44 in the hospital and the primary
care setting, respectively. More than half of the study sample gender was female, and the
majority of patients were of Malay ethnicity. Concerning the comorbidities tracked in the
study population, about 22.6% of the study subjects had an underlying atherosclerotic cardio-
vascular disease (ASCVD). Table 2 displays an overview of the distribution of patients’ distri-
bution and study sites, including their demographic characteristics and underlying diseases.
Patterns of statin therapy prescriptions
A considerable portion of subjects was receiving moderate intensity simvastatin therapy. Also,
2.6% of the study subjects were prescribed with combination LLT therapy, and only 6.4% were
initiated on high-intensity statin therapy. Table 3 provides a summary of the description of
the prescribing of LLT for patients with T2DM in all study sites.
Table 2. Study sites distribution, demographic characteristics, and main underlying diseases among the study
subjects.
Frequency (N) Percent (%)
Study site (s)
Hospital 1 195 12.2
Hospital 2 198 12.4
Hospital 1� 191 12.0
Hospital 2� 198 12.4
PCC 1 104 6.6
PCC 2 99 6.2
PCC 3 100 6.2
PCC 4 101 6.3
PCC 1� 100 6.2
PCC 2� 100 6.2
PCC 3� 108 6.8



















Note: � refer to data related to the post-intervention phase.
https://doi.org/10.1371/journal.pone.0220458.t002
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The impact of academic detailing on the prescribing practice in the
interventional study sites
The data from all study sites targeted by the intervention were grouped as both pre and post-
intervention phases of the data assessment phase. A sample of 399 cases from the pre-interven-
tion phase and 399 cases from the post-intervention phase were considered for analysis. A
Chi-square test of homogeneity was run noting that the two multinomial probability distribu-
tions were not equal in the population, Χ2 (2) = 18.390, p< 0.001. However, there was a statis-
tically, significant difference between the two proportions. The observed frequencies and
percentages of the outcomes of the LLT prescribing evaluation between the two phases of data
collection are presented in Table 4.
Post hoc analysis involved pairwise comparisons using multiple z-tests of two proportions
with a Bonferroni correction. As we have three pairwise comparisons in the post hoc analysis,
statistical significance was accepted at p< 0.0166. There was a statistically significant differ-
ence in the proportion of appropriate LLT prescribing between the post-intervention phases
compared to the pre-intervention phase (n = 246, 61.7% versus n = 188, 47.1%), p = 0.001.
Moreover, there was a statistically, significant difference in the proportion of inappropriate
LLT prescribing between the post-intervention phases compared to the pre-intervention phase
Table 3. Summary of the prescribed LLT and their relative intensities among T2DM subjects.
Frequency (N) Percent (%)
Status of the Prescribed LLT
No LLT 322 20.2
Simvastatin 1,084 67.8
Atorvastatin 120 7.5
Other Statin Monotherapy 7 0.4
Statin Combination Therapy 41 2.6
Non-statin Monotherapy 24 1.5
The intensity of the Prescribed Statin therapy
Low intensity 144 9
Moderate Intensity 1005 62.9
High Intensity 103 6.4
No Statin Therapy 346 21.7
1,598 100.0
https://doi.org/10.1371/journal.pone.0220458.t003
Table 4. Pre and post-intervention evaluation of LLT prescribing in all intervention study sites.
Evaluation of LLT regimen Study sites (Intervention) Total
Pre Intervention Post Intervention
Appropriate Count 188a 246b 434
% within Study site 47.1% 61.7% 54.4%
Potentially Inappropriate Count 86a 72a 158
% within Study site 21.6% 18.0% 19.8%
Inappropriate Count 125a 81b 206
% within Study site 31.3% 20.3% 25.8%
Total Count 399 399 798
% within Study site 100.0% 100.0% 100.0%
Each subscript letter denotes a subset of the study site categories whose column proportions do not differ significantly from each other at the 0.05 level.
https://doi.org/10.1371/journal.pone.0220458.t004
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(n = 81, 20.3% versus n = 125, 31.3%). No other pairwise comparisons were associated with
statistically significant differences. Fig 2 shows the frequency differences in each category of
prescribing evaluation in the intervention study sites.
The overall impact of academic detailing on the prescribing practice in the
control study sites
The assessment of LLT prescribing in the control study sites was considered as per the study
design to produce a more rigorous estimation of the impact of the educational intervention. A
sample of 398 cases from the pre-intervention phase and 402 cases from the post-intervention
phase were considered for the analysis. A Chi-square test of homogeneity was run where the
two multinomial probability distributions were not equal in the population, Χ2 (2) = 3.031,
p = 0.220. There was no statistically, significant difference between the two proportions. The
observed frequencies and percentages of the outcomes of the LLT prescribing evaluation
between the two phases of data collection are presented in Table 5.
There was an increase in the appropriate LLT prescribing and a decrease in the inappropri-
ate LLT prescribing. However, the magnitude of these differences was relatively small in order
to show any statistical significance. Fig 3 displays the frequency differences in each category of
prescribing evaluation in the control study sites.
Discussion
According to the results, it is shown that there is a statistically significant difference in the pro-
portions of appropriate statin therapy prescribing between the intervention and control
Fig 2. Evaluation of LLT prescribing before and after the academic detailing in the intervention study sites.
https://doi.org/10.1371/journal.pone.0220458.g002
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groups. The educational intervention in the form of the academic detailing program was
found to have a positive impact on the promotion of the quality of evidence-based patient
care. Similarly, the results of a US study showed that a significant gap in the evidence-based
statin therapy prescribing among patients with T2DM could be filled through brief pharmacist
intervention targeting healthcare providers [26]. In comparison with our study, the US study
proposed an intervention designed as a phone call and fax template, while our study proposed
intervention in the form of an academic detailing program involving direct interaction with
the healthcare providers with relatively larger sample size.
Moreover, our intervention results are consistent with the previously reported statistically
significant findings of a study that evaluated the impact of the pharmacist-led intervention on
Table 5. Pre and post-intervention evaluation of LLT prescribing in all control study sites.
Evaluation of LLT regimen Study site Total
Control Pre Intervention Control Post Intervention
Appropriate Count 214 228 442
% within Study site 53.8% 56.7% 55.3%
Potentially Inappropriate Count 105 113 218
% within Study site 26.4% 28.1% 27.3%
Inappropriate Count 79 61 140
% within Study site 19.8% 15.2% 17.5%
Total Count 398 402 800
% within Study site 100.0% 100.0% 100.0%
https://doi.org/10.1371/journal.pone.0220458.t005
Fig 3. Evaluation of LLT prescribing before and after the academic detailing in the control study sites.
https://doi.org/10.1371/journal.pone.0220458.g003
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improving the achievement of cholesterol treatment goals and statin therapy prescribing
among patients with high CVD risk in the UK primary care setting [18]. Compared to our
study, both studies shared the same objectives of enhancing statin therapy prescribing
although, in our study, the achievement of treatment goals as one of the evaluation outcomes
for the intervention was not considered. Furthermore, the positive impact of our intervention
in this study is consistent with the reported positive impact of the pharmacist-managed pro-
gram on increasing the percentage of T2DM patients who achieved treatment goals compared
with patients treated with usual care [10]. Furthermore, a positive impact was also reported fol-
lowing cardiovascular educational intervention targeted at healthcare professionals in the pri-
mary care setting [27].
On the other hand, a study aimed to assess the impact of the pharmacists’ intervention on
increasing the guideline-directed statin therapy use among patients with acute coronary syn-
drome did not show a significant impact of the intervention on the overall percentage of
patients receiving statin therapy [28]. This finding contradicts the results of our study, where
the intervention offered by academic-affiliated pharmacists’ showed a significantly positive
impact on the overall percentage of patients receiving statin therapy.
To summarise, the academic detailing program in our study showed a positive impact on
statin therapy prescribing with a statistically significant difference in the percentage of the
overall appropriate prescribing in both the hospital and primary care setting. Similar positive
findings were frequently reported in the literature. In contrast, some studies showed the mod-
est academic detailing impact that was not associated with statistically significant differences
in the overall prescribing. Furthermore, there were some noted differences between a few stud-
ies regarding the final design of the academic detailing program, number of academic detailers,
the presence of the follow-up period, and the sample size of healthcare providers and patients.
In future, it is proposed to investigate the impact of these highlighted differences on the overall
efficiency of the program particularly in the settings, which were not associated with satisfac-
tory prescribing outcomes following the implementation of an academic detailing program.
Limitations
According to the quasi-experimental design that our study applied, it would be difficult to
claim that our findings could be generalized to the Malaysian T2DM population. The majority
of study subjects were of Malay ethnicity; this may limit the representativeness of the findings,
especially in locations where non-Malay subjects represent the majority. Moreover, we did
compare both groups once after the educational intervention, so we disclose that lack of differ-
ent time-based assessment at different points is a limitation of our work. Although previous
research did not support major differences in the prescribing assessment at different time
points [23].
Conclusion
Our study reinforced the effect of prescribing-improvement interventions focussing on health-
care professionals who could potentially contribute towards the optimization of medications
for CVD prophylaxis among T2DM patients. Also, following the comparison of the appropri-
ate statin therapy prescribing before and after the educational intervention in both interven-
tion and control groups, the academic detailing program was found to be significantly
associated with a positive impact on the overall statin therapy prescribing among patients with
T2DM. Accordingly, these results may be considered for further testing on a larger scale in the
Malaysian clinical setting to promote evidence-based statin therapy use.
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